BASDAI

Global Ankylosing Spondylitis Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, General Health, Medical specialties, Musculoskeletal system, Clinical medicine, Rheumatology, Skeletal disorders, Spondylitis, Ankylosing spondylitis, Pelvis, Bechterew, Sacroiliac joint, Arthritis, BASDAI

b'The "Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study.

Key Points: 
  • b'The "Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nAnkylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual\'s spine, starting from lower back sacral bones.
  • Ankylosing spondylitis is started from an individual\'s sacroiliac joints, where the spinal cord connects with the pelvic girdle.
  • According to the recent population estimates the prevalence rate of ankylosing spondylitis in the U.S. is around 0.2-0.5 percent and based on market data from multiple countries the global incidence rate stood at 0.4-14 per 100,000 individuals.\n'

UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

Retrieved on: 
Friday, June 14, 2019
Medical specialties, Medicine, Health, Rheumatology, Arthritis, Autoimmune diseases, RTT, Ankylosing spondylitis, Axial spondyloarthritis, BASDAI, Spondyloarthropathy, Quality of life

The safety and efficacy of bimekizumab have not been established, and it is not approved by any regulatory authority worldwide.

Key Points: 
  • The safety and efficacy of bimekizumab have not been established, and it is not approved by any regulatory authority worldwide.
  • Bimekizumab is now in Phase 3 trials, where the safety and efficacy are being evaluated in AS, non-radiographic axial spondyloarthritis, psoriatic arthritis (PsA) and psoriasis.
  • The objective of this further analysis was to assess the impact of bimekizumab on patient-reported and quality of life (QoL) outcomes at Week 12 in these patients.
  • Secondary and other endpoints included BASDAI, 50% improvement in BASDAI (BASDAI 50), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life (ASQoL) and Patient's Global Assessment of Disease Activity (PGADA) at Week 12.

Ankylosing Spondylitis Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stages, Drug Mechanism Classes, & Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 13, 2019
Health, Clinical trials, Pharmaceutical, Medical specialties, Medicine, Health, Rheumatology, RTT, Ankylosing spondylitis, Arthritis, Pharmaceutical industry, Clinical trial, Axial spondyloarthritis, BASDAI

The "Global Ankylosing Spondylitis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ankylosing Spondylitis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report, Ankylosing Spondylitis Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Ankylosing Spondylitis market.
  • It covers emerging therapies for Ankylosing Spondylitis in active clinical development stages including early and late stage clinical trials.
  • The report provides Ankylosing Spondylitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Retrieved on: 
Monday, October 22, 2018
Medicine, Clinical medicine, Monoclonal antibodies, Immunosuppressants, Immunology, Rheumatology, Clinical research, TNF inhibitors, Ankylosing spondylitis, Ixekizumab, Adalimumab, BASDAI

The analyses are part of a clinical development program that aims to evaluate Taltz (ixekizumab) across various populations of patients with AS.

Key Points: 
  • The analyses are part of a clinical development program that aims to evaluate Taltz (ixekizumab) across various populations of patients with AS.
  • COAST-V, which included 341 patients, is the first Phase 3 study of Taltz among patients with AS who had never received a biologic disease-modifying anti-rheumatic drug (bDMARD).
  • It also is the first study to include both a placebo control arm and active reference arm (adalimumab).
  • BASDAI50: 42 percent of patients treated with Taltz every four weeks, 43 percent of patients treated with Taltz every two weeks and 17 percent of patients treated with placebo achieved a Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50).